Investors interested in Medical - Instruments stocks are likely familiar with Integer (ITGR) and SONOVA HOLDING (SONVY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, ...

According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry ...

PLANO, Texas, April 29, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced participation in the 2025 Bank of America Securities Health Care Conference, to be held May 13-15, 2025, in Las Vegas. Members of the Integer executive leadership team will participate in a fireside chat on Wednesday, May 14, at 10:00 a.m. PT. Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical dev ...

Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.31 in the first quarter of 2025, which improved 14.9% year over year. The figure topped the Zacks Consensus Estimate by 3.2%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP loss per share for the quarter was 66 cents, against EPS of 59 cents in the p ...

Integer (ITGR) Q1 2025 Earnings Call April 25, 2025 12:52 AM ET Company Participants Sanjiv Arora - SVP, Strategy, Business Development and IRJoseph Dziedzic - President & CEOPayman Khales - COODiron Smith - Executive VP & CFORichard Newitter - Managing DirectorNathan Treybeck - Equity Research Vice PresidentAndrew Cooper - VP - Equity ResearchJoanne Wuensch. - Managing DirectorSuraj Kalia - Managing Director Conference Call Participants Brett Fishbin - Vice President & Equity Research AnalystCraig Bijou - ...

Integer Holdings Corporation First Quarter 2025 Earnings Conference Call April 24, 2025 Integer Holdings Corporation First Quarter 2025 Earnings Conference Call 9 a.m. Eastern Time, April 24, 2025 Management Attendees: Diron Smith Executive Vice President, Chief Financial Officer Sanjiv Arora Senior Vice President, Strategy, Business Development & Investor Relations ITGR: 1Q25 Earnings Conference Call | April 24, 2025 | Page 2 Joe Dziedzic President, Chief Executive Officer Payman Khales President and CEO E ...

Integer (ITGR) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 3.15%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.46 per share when it actually produced earnings of $1.43, delivering a surprise of -2.05%. Over the last fou ...

EXHIBIT 99.1 Integer Holdings Corporation Reports First Quarter 2025 Results ~ Strong start to the year with 1Q25 financial results ~ ~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ "Integer started the year off strong with first quarter 2025 sales growing at 7% year-over-year as we continue to execute our strategy by launching new products and adding capabilities in targeted growth markets. Integer also delivered 14% adjusted operating income growth," said Jos ...

Leadership Transition - Joseph Dziedzic will retire as President and CEO of Integer Holdings Corporation effective October 24, 2025, and will step down from the Board of Directors [1] - Payman Khales, currently the Chief Operating Officer, will assume the role of President and CEO and join the Board at that time [1] - To ensure a smooth transition, Dziedzic will serve as an advisor to the company until March 31, 2026 [1] Achievements and Strategy - Dziedzic's leadership over the past eight years has driven significant growth and value creation for Integer, focusing on high-growth markets and unmet patient needs [2] - Under Dziedzic, the company accelerated investments in differentiated technologies and implemented the Integer Production System to enhance manufacturing consistency [2] - Integer is currently achieving above-market organic sales growth with expanding margins, positioning the company for continued growth [2] Incoming CEO Profile - Payman Khales has been with Integer since 2018, initially as President of the Cardio & Vascular business, where he successfully doubled sales in seven years [3][5] - As COO, Khales has overseen both of Integer's business units and has been integral to the development and execution of the company's strategy [3][5] - Khales holds an Executive MBA from Indiana University's Kelley School of Business and a Bachelor of Science in Mechanical Engineering from École Polytechnique de Montréal [6] Company Overview - Integer Holdings Corporation is a leading medical device contract development and manufacturing organization, serving cardiac rhythm management, neuromodulation, and cardio and vascular markets [7] - The company is committed to enhancing patient lives through innovative, high-quality products and solutions, with brands including Greatbatch Medical and Lake Region Medical [7]

Core Insights - Integer (ITGR) is expected to report quarterly earnings of $1.27 per share, reflecting an 11.4% increase year-over-year, with revenues projected at $431.84 million, a 4.1% increase from the previous year [1] - Over the last 30 days, the consensus EPS estimate has been revised upward by 1.6%, indicating a positive reassessment by analysts [1][2] Revenue Estimates - Analysts predict 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' to reach $162.26 million, showing a year-over-year increase of 3.8% [4] - 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' is estimated at $22.58 million, reflecting a significant decline of 22.5% from the prior-year quarter [4] - 'Sales- Medical Sales- Cardio & Vascular' is expected to be $247.02 million, indicating an 11.4% increase compared to the same quarter last year [5] Market Performance - Integer shares have decreased by 1.5% over the past month, contrasting with the Zacks S&P 500 composite's decline of 8.9% [6] - The company holds a Zacks Rank of 3 (Hold), suggesting it is likely to perform in line with the overall market in the near term [6]